These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2004369)

  • 21. Improved therapeutic index with sequential N-phosphonacetyl-L-aspartate plus high-dose methotrexate plus high-dose 5-fluorouracil and appropriate rescue.
    Martin DS; Stolfi RL; Sawyer RC; Spiegelman S; Young CW
    Cancer Res; 1983 Oct; 43(10):4653-61. PubMed ID: 6603903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The enhancement of the frequency of resistance to N-phosphonoacetyl-L-aspartate and methotrexate by 1-beta-D-arabinofuranosylcytosine: the effect of dipyridamole.
    Goz B; Jeffs L
    J Pharmacol Exp Ther; 1994 Aug; 270(2):480-4. PubMed ID: 8071840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.
    Kemeny N; Schneider A; Martin DS; Colofiore J; Sawyer RC; Derby S; Salvia B
    Cancer Res; 1989 Aug; 49(16):4636-9. PubMed ID: 2472883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Normal diploid human and rodent cells lack a detectable frequency of gene amplification.
    Tlsty TD
    Proc Natl Acad Sci U S A; 1990 Apr; 87(8):3132-6. PubMed ID: 2326271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum uridine levels in patients receiving N-(phosphonacetyl)-L-aspartate.
    Karle JM; Anderson LW; Erlichman C; Cysyk RL
    Cancer Res; 1980 Aug; 40(8 Pt 1):2938-40. PubMed ID: 7388844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hamster cells with increased rates of DNA amplification, a new phenotype.
    Giulotto E; Knights C; Stark GR
    Cell; 1987 Mar; 48(5):837-45. PubMed ID: 3815526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kinetic parameters of aspartate transcarbamylase in human normal and tumoral cell lines.
    Baillon J; Guichard M; Malaise EP; Hervé G
    Cancer Res; 1983 May; 43(5):2277-82. PubMed ID: 6831451
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TPA enhancement of the recovery of methotrexate and N-phosphonacetyl L-aspartate resistant mouse 3T6 cell clones is associated with transient alterations of cell cycle progression.
    Szallasi A; Fox M; Kinsella AR
    Int J Cancer; 1988 Jul; 42(1):84-6. PubMed ID: 3391707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of 12-O-tetradecanoylphorbol-13-acetate on selection of drug-resistant phenotypes in rodent cells.
    Bojan F; Kinsella AR; Fox M
    IARC Sci Publ; 1984; (56):265-73. PubMed ID: 6536598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I clinical study of N-(phosphonacetyl)-L-aspartic acid (PALA).
    Valdivieso M; Moore EC; Burgess AM; Marti JR; Russ J; Plunkett W; Loo TL; Bodey GP; Freireich EJ
    Cancer Treat Rep; 1980; 64(2-3):285-92. PubMed ID: 7407763
    [No Abstract]   [Full Text] [Related]  

  • 31. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
    Grem JL; McAtee N; Steinberg SM; Hamilton JM; Murphy RF; Drake J; Chisena T; Balis F; Cysyk R; Arbuck SG
    Cancer Res; 1993 Oct; 53(20):4828-36. PubMed ID: 8402669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amplification potential in preneoplastic and neoplastic Syrian hamster embryo fibroblasts transformed by various carcinogens.
    Jonczyk P; White A; Lum K; Barrett JC; Tlsty TD
    Cancer Res; 1993 Jul; 53(13):3098-102. PubMed ID: 8319217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pharmacologic modulation of 5-fluorouracil with folinic acid, methotrexate, trimetrexate, and n-phosphonacetyl-l-aspartic acid (PALA). Mechanisms of the interactions and clinical data.
    Machover D
    Bull Cancer; 1994 Dec; 81 Suppl 2():74s-77s. PubMed ID: 7727863
    [No Abstract]   [Full Text] [Related]  

  • 34. Phase I study of N-(phosphonacetyl)-L-aspartic acid (PALA).
    Kovach JS; Schutt AJ; Moertel CG; O'Connell MJ
    Cancer Treat Rep; 1979; 63(11-12):1909-12. PubMed ID: 526923
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review.
    Grem JL; King SA; O'Dwyer PJ; Leyland-Jones B
    Cancer Res; 1988 Aug; 48(16):4441-54. PubMed ID: 3293772
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of N-(phosphonacetyl)-L-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of aspartate transcarbamylase.
    Johnson RK; Swyryd EA; Stark GR
    Cancer Res; 1978 Feb; 38(2):371-8. PubMed ID: 620408
    [No Abstract]   [Full Text] [Related]  

  • 37. N-(phosphonacetyl)-L-aspartate synergistically enhances the cytotoxicity of 5-fluorouracil/interferon-alpha-2a against human colon cancer cell lines.
    Wadler S; Mao X; Bajaj R; Hallam S; Schwartz EL
    Mol Pharmacol; 1993 Nov; 44(5):1070-6. PubMed ID: 8246910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 1-beta-D-arabinofuranosylcytosine enhancement of resistance to several antineoplastic drugs in mammalian tissue culture cells.
    Goz B; Carl PL; Tlsty TD
    Mol Pharmacol; 1989 Sep; 36(3):360-5. PubMed ID: 2571071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate.
    Chan TC; Markman M; Cleary S; Howell SB
    Cancer Res; 1986 Jun; 46(6):3168-72. PubMed ID: 3698032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I trial of N-(Phosphonacetyl)-L-aspartic acid (PALA).
    Ervin TJ; Blum RH; Meshad MW; Kufe DW; Johnson RK; Canellos GP
    Cancer Treat Rep; 1980; 64(10-11):1067-71. PubMed ID: 7459892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.